

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License number

22-17307-01

Docket or Reference number

030-12533

Amendment No. 05

Mercy Medical Center  
Department of Radiology  
4050 Coon Rapids Blvd.  
Coon Rapids, MN 55443

In accordance with application dated March 6, 1985, License Number 22-17307-01 is amended as follows:

Items 6., 7., 8. and 9. are amended to add:

6. Byproduct, source,  
and/or special nuclear  
material

7. Chemical and/or  
physical form

8. Maximum amount that  
licensee may possess  
at any one time  
under this license

G. Xenon-133

G. Gas or gas in solution  
that is the subject  
of an active (i.e., not  
withdrawn or terminated)  
"New Drug Application"  
(NDA) approved by FDA or  
an active (i.e., not  
withdrawn, terminated  
or on "clinical hold")  
"Notice of Claimed  
Investigational Exemption  
for a New Drug" (IND)  
that has been accepted  
by FDA

G. 100 millicuries

9. Authorized Use

G. Blood flow studies. Pulmonary function studies.

Conditions 12. and 16. are amended to read:

12. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:

William Kinney, M.D.

Groups I, II and III  
Soluble phosphorus-32 for treatment  
of polycythemia vera, leukemia  
and bone metastases  
Iodine-131 for treatment of  
hyperthyroidism and cardiac  
dysfunction  
In vitro studies  
Xenon-133

8507240373 850628  
REG3 LIC30  
22-17307-01 PDR

COPY 2

11/11/30 SK JUN 28 1985

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License number

22-17307-01

Docket or Reference number

030-12533

Amendment No. 05

A. S. Nesse, M.D.

Groups I, II and III  
Soluble phosphorus-32 for treatment  
of polycythemia vera, leukemia  
and bone metastases  
Iodine-131 for treatment of  
hyperthyroidism and cardiac  
dysfunction  
In vitro studies  
Xenon-133

L. O. Wigdahl, M.D.

Groups I, II and III  
Soluble phosphorus-32 for treatment  
of polycythemia vera, leukemia  
and bone metastases  
Iodine-131 for treatment of  
hyperthyroidism and cardiac  
dysfunction  
In vitro studies  
Xenon-133

Carroll N. Hess, M.D.

Groups I, II and III  
Soluble phosphorus-32 for treatment  
of polycythemia vera, leukemia  
and bone metastases  
Iodine-131 for treatment of  
hyperthyroidism and cardiac  
dysfunction  
In vitro studies  
Xenon-133

John A. Tobin, M.D.

Groups I, II and III  
Soluble phosphorus-32 for treatment  
of polycythemia vera, leukemia  
and bone metastases  
Iodine-131 for treatment of  
hyperthyroidism and cardiac  
dysfunction  
In vitro studies  
Xenon-133

James L. Tuohy, M.D.

Groups I, II and III

Steven M. Begich, M.D.

Groups I, II and III  
Soluble phosphorus-32 for treatment  
of polycythemia vera, leukemia  
and bone metastases  
Iodine-131 for treatment of  
hyperthyroidism and cardiac  
dysfunction  
In vitro studies  
Xenon-133

COPY

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License number

22-17307-01

Docket or Reference number

030-12533

Amendment No. 05

Joseph M. Collins, M.D.

Groups I, II and III

Xenon-133

In vitro studies

James Kollitz, M.D.

Groups I, II and III

Soluble phosphorus-32 for treatment  
of polycythemia vera, leukemia  
and bone metastases

Iodine-131 for treatment of  
hyperthyroidism and cardiac  
dysfunction

In vitro studies

Xenon-133

Leonard Langer, M.D.

Groups I, II and III

Soluble phosphorus-32 for treatment  
of polycythemia vera, leukemia  
and bone metastases

Iodine-131 for treatment of  
hyperthyroidism and cardiac  
dysfunction

In vitro studies

Xenon-133

Paul R. Kollitz, M.D.

Groups I, II and III

Xenon-133

In vitro studies

Peter N. Constantini

Groups I and II

Xenon-133

In vitro studies

Iodine-131 for treatment of  
hyperthyroidism and cardiac  
dysfunction

For the U.S. Nuclear Regulatory Commission

Original Signed

By William J. Adam, Ph.D.

Materials Licensing Section, Region III

Date June 28, 1985

COPY